0000000000352291
AUTHOR
Stephan Schmitz
showing 4 related works from this author
Final results of the AIO 0307 study: A controlled, randomized, double-blind phase II study of FOLFOX6 or FOLFIRI combined with sorafenib (S) versus p…
2013
3586 Background: The oral multikinase inhibitor Sorafenib (S) inhibits angiogenesis and tumor growth in preclinical models of CRC. This study investigated the addition of S to standard 2nd line chemotherapy (CTX). Methods: Patients (pts) with mCRC and progression after first-line therapy with an oxaliplatin- or irinotecan based fluoropyrimidine containing regimen ± Bevacizumab (Bev), were randomized to receive chemotherapy (CTX) (FOLFOX6 or FOLFIRI) + S (400 mg bid) or CTX + placebo (P). 240 pts were planned to be enrolled to ensure a power of 80% if median progression-free survival (PFS) with S is increased by 2 months compared to P. Results: Between 04/09 and 10/11, 101 pts were enrolled…
The Tan 2Θ Theorem in fluid dynamics
2017
We show that the generalized Reynolds number (in fluid dynamics) introduced by Ladyzhenskaya is closely related to the rotation of the positive spectral subspace of the Stokes block-operator in the underlying Hilbert space. We also explicitly evaluate the bottom of the negative spectrum of the Stokes operator and prove a sharp inequality relating the distance from the bottom of its spectrum to the origin and the length of the first positive gap.
Combined Immuno-Chemotherapy (R-CHOP) Results in Significantly Superior Response Rates and Time to Treatment Failure in First Line Treatment of Patie…
2004
Abstract Lymphomplasmocytoid/ic immunocytoma (LP-IC), including Waldenstrom’s macro-globulinemia and lymphoplasmacytoid lymphoma according to the Kiel classification (the latter one subsummed as a variant of B-CLL in the WHO classification), is an indolent lymphoma, which is incurable by conventional chemotherapy in the advanced stage of disease. The anti-CD20 antibody Rituximab has shown remarkable activity in indolent lymphomas, in particular when combined with chemotherapy. Based on these results the GLSG investigated the efficacy of a combined immuno-chemotherapy (R-CHOP: Rituximab 375 mg/m2 d0-1; cyclophosphamide 750 mg/m2 d1; doxorubicine 50 mg/m2 d1; vincristine 1.4 mg/m2 d1; prednis…
Diagonalization of indefinite saddle point forms
2020
We obtain sufficient conditions that ensure block diagonalization (by a direct rotation) of sign-indefinite symmetric sesquilinear forms as well as the associated operators that are semi-bounded neither from below nor from above. In the semi-bounded case, we refine the obtained results and, as an example, revisit the block Stokes operator from fluid dynamics.